Biotest

Biotest submitted a Biologics License Application to the FDA for its Fibrinogen, targeting fibrinogen deficiency treatment. Following an EU application in October 2024, FDA approval could enhance sales and patient care. Fibrinogen offers a safer, more convenient alternative to current treatments, with clinical trials demonstrating its efficacy and safety.

Biotest submitted a Biologics License Application for Fibrinogen to the FDA, aiming to treat fibrinogen deficiency. Following an EU application in October 2024, the FDA's decision is expected by end of 2025. Biotest's Fibrinogen offers a safer, more convenient treatment option compared to current standards, with potential to significantly improve sales and patient care.

Biotest submitted a Biologics License Application for its Fibrinogen to the FDA, aiming to treat fibrinogen deficiency. Following an EU application in October 2024, FDA approval could enhance sales and patient care. Biotest's Fibrinogen offers a safer, more convenient treatment option compared to current standards, with clinical trials demonstrating its efficacy and safety.

Biotest submitted a Biologics License Application to the FDA for its Fibrinogen, aiming to treat fibrinogen deficiency. Following an EU application in October 2024, FDA approval could enhance sales and patient care. Biotest's Fibrinogen offers a safer, more convenient alternative to current treatments, with clinical trials demonstrating its efficacy and safety.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

The immunoglobulin market, valued at US$ 13.36 billion in 2023, is projected to reach US$ 28.70 billion by 2034, driven by its use in treating immunodeficiency and other applications. Key growth factors include immunodeficiency disorders, infections, and thrombocytopenia. North America leads with a 46% share, while Asia-Pacific is expected to grow fastest due to increased health spending and prevalence of autoimmune diseases. Recent advancements include subcutaneous injection therapies and acquisitions by major pharmaceutical companies.